title: [The effectiveness and acceptability of oral contraceptives (Logest), containing 20 micrograms ethinylestradiol and 75 micrograms gestodene].
abstract: OBJECTIVE
  The aim of the study was to evaluate the efficacy and acceptability of the use of oral contraceptives Logest, containing 20 micrograms ethinylestradiol and 75 micrograms gestodene (in one tablet).
  
  
  METHODS
  Observational study (during the period of six months) on the healthy women visiting gynecological clinics and asking for establishment of contraception with the use of oral contraceptives.
  
  
  METHODS
  The observation was carried out on 800 patients who were included (with use including/excluding criteria) to the study. The study was carried out during the period of October 1999-March 2001. Patients were asked to use the Logest intermittently during the period of 6 months (21 days of administration followed by 7 days break, and than again 21 days of administration etc). The administration of Logest was followed up. Basic examination and qualification for the use of oral contraceptive was taken during the first visit. Re-examinations were taken after 3 and 6 month of usage of the study drug.
  
  
  RESULTS
  High efficacy, good tolerance and acceptability of Logest administration was observed. Neither cases of non effectiveness, nor serious adverse events, during the Logest administration were reported.
  
  
  CONCLUSIONS
  95.7% of the patients which completed the study, declared that the oral contraception with use of Logest was "very well accepted" or "well accepted".
authors.affiliation: Szkoła Zdrowia Publicznego i Medycyny Społecznej CMKP w Warszawie.
authors.forename: Medard M
authors.initials: MM
authors.lastname: Lech
authors.forename: Ewa J
authors.initials: EJ
authors.lastname: Swiatek
mesh_terms: D000293:Adolescent; D000328:Adult; D003268:Contraception Behavior; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D009652:Norpregnenes / Q000008:administration & dosage* / Q000009:adverse effects; D010342:Patient Acceptance of Health Care / Q000706:statistics & numerical data; D010817:Physician-Patient Relations; D011044:Poland / Q000453:epidemiology; D013997:Time Factors; D016387:Women's Health
chemical_list: D003277:Contraceptives, Oral, Combined; D003280:Contraceptives, Oral, Synthetic; D004338:Drug Combinations; D009652:Norpregnenes; C033273:Gestodene; D004997:Ethinyl Estradiol